BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fasenra (Benralizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fasenra (Benralizumab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05692180-1322@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT05692180)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: A Multicentr
 e\, Randomised\, Double-blind\, Parallel Group\, Placebo-controlled\, Time
 -to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benra
 lizumab in Paediatric Patients With Severe Eosinophilic Asthma\nEstimated 
 primary completion: 23 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/benralizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05692180
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385236-1322@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Fasenra (Benralizumab): Phase 4 readout est. (NCT06385236)
DESCRIPTION:Fasenra (Benralizumab)\, phase 4\, Asthma.\nStudy: Leveraging P
 harmacogenomics in Asthma for Predication\, Mechanism and Endotyping\nEsti
 mated primary completion: 30 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/benralizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06385236
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654842-1322@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Fasenra (Benralizumab): Phase 4 readout est. (NCT07654842)
DESCRIPTION:Fasenra (Benralizumab)\, phase 4\, Asthma.\nStudy: Fasenra: An 
 Asthma Study\nEstimated primary completion: 1 September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/benralizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07654842
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06512883-1322@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT06512883)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3.\nStudy: A Trial to Investigat
 e Benralizumab in Children With Eosinophilic Diseases\nEstimated primary c
 ompletion: 20 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/benralizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06512883
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734884-1322@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290105
DTEND;VALUE=DATE:20290106
SUMMARY:Fasenra (Benralizumab): Phase 2 readout est. (NCT06734884)
DESCRIPTION:Fasenra (Benralizumab)\, phase 2.\nStudy: Interest of a Targete
 d Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (
 DRESS Syndrome)\nEstimated primary completion: 5 January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/benralizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06734884
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444567-1322@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20291227
DTEND;VALUE=DATE:20291228
SUMMARY:Fasenra (Benralizumab): Phase 3 readout est. (NCT07444567)
DESCRIPTION:Fasenra (Benralizumab)\, phase 3\, Asthma.\nStudy: Roll-over St
 udy for Participants Who Have Completed a Previous Clinical Study With Ben
 ralizumab (Fasenra) and Benefit From Continued Treatment\nEstimated primar
 y completion: 27 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/benralizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07444567
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501807-1322@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20340902
DTEND;VALUE=DATE:20340903
SUMMARY:Fasenra (Benralizumab): Phase na readout est. (NCT06501807)
DESCRIPTION:Fasenra (Benralizumab)\, phase na.\nStudy: BIOlogics in Severe 
 Nasal POlyposis SurvEy.: a French Registry\nEstimated primary completion: 
 2 September 2034. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ben
 ralizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06501807
URL:https://assetmemo.bio/drug/benralizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
